Quality statement 6: Monitoring systemic treatment
Quality statement
People with psoriasis receiving systemic treatment are monitored in accordance with locally agreed protocols.
Rationale
Systemic treatment for psoriasis poses a risk of adverse events, for which careful monitoring is needed. It is essential that monitoring is in accordance with national medicine guidelines to minimise this risk. Where shared care arrangements are in place, it is important that the roles and responsibilities of healthcare professionals involved in monitoring people with psoriasis receiving systemic treatment are clearly outlined in a formalised local agreement.
Quality measures
The following measures can be used to assess the quality of care or service provision specified in the statement. They are examples of how the statement can be measured, and can be adapted and used flexibly.
Structure
Evidence of local arrangements for people with psoriasis receiving systemic treatment to be monitored in accordance with locally agreed protocols.
Data source: Local data collection.
What the quality statement means for different audiences
Service providers ensure that systems are in place for people with psoriasis receiving systemic treatment to be monitored in accordance with locally agreed protocols.
Healthcare practitioners ensure that people with psoriasis receiving systemic treatment are monitored in accordance with locally agreed protocols.
Commissioners ensure that they commission services for people with psoriasis receiving systemic treatment to be monitored in accordance with locally agreed protocols.
People with psoriasis receiving drug treatment known as 'systemic treatment' are monitored according to a locally agreed procedure.
Source guidance
Psoriasis: assessment and management. NICE guideline CG153 (2012, updated 2017), recommendations 1.5.1.1 and 1.5.1.5
Definitions of terms used in this quality statement
Systemic treatment
Systemic treatment includes targeted immunomodulatory treatments and conventional systemic treatments.
Responsibility for use of systemic treatment should be in specialist consultant-led settings only. Certain aspects of supervision and monitoring may be delegated to other healthcare professionals and completed in non-specialist settings. In such cases, the arrangements should be formalised.
Monitoring
Monitoring should be in accordance with locally agreed protocols that incorporate national accredited medicine guidelines and policy.
Relevant national accredited drug guidelines include:
-
Psoriasis: assessment and management (2012, updated 2017) NICE guideline CG153
-
Guidelines for biologic therapy for psoriasis: a rapid update (2020) British Association of Dermatologists
-
Guidelines on the efficacy and use of acitretin in dermatology (2010) British Association of Dermatologists